Fast-Made cell therapy tested as potential Game-Changer for Tough-to-Treat lupus
NCT ID NCT07233642
Summary
This early-stage study is testing a new, quickly manufactured cell therapy for people with severe lupus that hasn't responded to standard drugs. Doctors take a patient's own immune cells, modify them to target harmful B cells thought to drive lupus, and infuse them back. The main goals are to see if this treatment is safe and if it can reduce lupus disease activity.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's Hospital of Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310052, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.